Spots Global Cancer Trial Database for contiguous stage ii mantle cell lymphoma

Every month we try and update this database with for contiguous stage ii mantle cell lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma	NCT00070447	Lymphoma	rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... yttrium Y 90 ib...	18 Years -	National Cancer Institute (NCI)
Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma	NCT00003280	Lymphoma	rituximab	18 Years - 120 Years	Swiss Group for Clinical Cancer Research
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma	NCT00017381	Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Stage I Adult D... Stage I Adult D... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenström Mac...	rituximab cyclophosphamid... filgrastim yttrium Y 90 ib... peripheral bloo...	18 Years - 70 Years	National Cancer Institute (NCI)
Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma	NCT00516412	Lymphoma	everolimus molecular respo...	18 Years -	Swiss Group for Clinical Cancer Research
Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy	NCT00727207	Lymphoma	everolimus	40 Years -	Technical University of Munich
Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma	NCT00278161	Leukemia Lymphoma	Pegfilgrastim Rituximab Cyclophosphamid...	18 Years - 70 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy	NCT00891137	Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic...	human myeloid p...	12 Years - 65 Years	Cellerant Therapeutics
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers	NCT00003163	Lymphoma Multiple Myelom...	filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera...	18 Years -	National Cancer Institute (NCI)
Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma	NCT00020943	Lymphoma	filgrastim rituximab carmustine cyclophosphamid... cytarabine doxorubicin hyd... etoposide leucovorin calc... methotrexate prednisone vincristine sul... peripheral bloo...	18 Years - 69 Years	Alliance for Clinical Trials in Oncology
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma	NCT00026429	Leukemia Lymphoma	denileukin dift...	18 Years -	National Cancer Institute (NCI)
Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma	NCT00003356	Lymphoma	aldesleukin rituximab	18 Years - 75 Years	University of Rochester
Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)	NCT00005626	Leukemia Lymphoma	Irinotecan	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma	NCT00003397	Lymphoma	filgrastim rituximab sargramostim carmustine cisplatin cyclophosphamid... dexamethasone etoposide gemcitabine hyd... melphalan paclitaxel bone marrow abl... peripheral bloo...	18 Years - 75 Years	University of Maryland, Baltimore
Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers	NCT00003572	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	peripheral bloo... mycophenolate m... tacrolimus allogeneic bone... radiation thera...	18 Years - 70 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma	NCT00740415	Lymphoma	rituximab bortezomib dexamethasone Bendamustine	65 Years - 80 Years	French Innovative Leukemia Organisation
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome	NCT00002989	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	busulfan cyclophosphamid... idarubicin melphalan radiation thera...	16 Years - 60 Years	National Cancer Institute (NCI)
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma	NCT01045928	Adult Non-Hodgk... Adult Grade III... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Cutaneous B-cel... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage I Adult B... Stage I Adult D... Stage I Adult D... Stage I Adult D... Stage I Adult I... Stage I Adult L... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenstrom Mac...	lenalidomide rituximab polymerase chai... nucleic acid se... polymorphism an... flow cytometry laboratory biom...	18 Years -	Case Comprehensive Cancer Center
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma	NCT02242097	Contiguous Stag... Noncontiguous S... Stage I Mantle ... Stage III Mantl... Stage IV Mantle...	ibrutinib laboratory biom...	18 Years -	Northwestern University
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy	NCT00003341	Anemia Leukemia Lymphoma Multiple Myelom...	epoetin alfa quality-of-life...	18 Years -	Memorial Sloan Kettering Cancer Center
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer	NCT00290641	Chronic Myelopr... Leukemia Lymphoma Myelodysplastic...	filgrastim graft-versus-tu... cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... umbilical cord ... radiation thera...	- 45 Years	Masonic Cancer Center, University of Minnesota
Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma	NCT00006252	Leukemia Lymphoma	fludarabine pho... Cyclophosphamid... PBSC G-CSF Donor lymphocyt...	- 69 Years	Alliance for Clinical Trials in Oncology
Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma	NCT00110006	Lymphoma	rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... positron emissi... fludeoxyglucose...	18 Years -	Case Comprehensive Cancer Center
Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma	NCT00101101	Lymphoma	Cyclophosphamid... Doxorubicin Vincristine Prednisone Dexamethasone Autologous Tumo... IL-2	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers	NCT00003163	Lymphoma Multiple Myelom...	filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera...	18 Years -	National Cancer Institute (NCI)
S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma	NCT00376961	Lymphoma	rituximab bortezomib cyclophosphamid... doxorubicin hyd... prednisone vincristine sul...	18 Years - 120 Years	SWOG Cancer Research Network
S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma	NCT00005089	Lymphoma	rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... radiation thera...	18 Years -	SWOG Cancer Research Network
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma	NCT02242097	Contiguous Stag... Noncontiguous S... Stage I Mantle ... Stage III Mantl... Stage IV Mantle...	ibrutinib laboratory biom...	18 Years -	Northwestern University
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma	NCT00026429	Leukemia Lymphoma	denileukin dift...	18 Years -	National Cancer Institute (NCI)
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia	NCT00004084	Leukemia Lymphoma	indium In 111 L... yttrium Y 90 ep...	18 Years -	Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma	NCT00003280	Lymphoma	rituximab	18 Years - 120 Years	Swiss Group for Clinical Cancer Research
Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma	NCT00018954	Leukemia Lymphoma	asparaginase cyclophosphamid... cytarabine daunorubicin hy... doxorubicin hyd... etoposide ifosfamide mercaptopurine methotrexate prednisone vincristine sul... conventional su... radiation thera...	-	National Institutes of Health Clinical Center (CC)
Bortezomib in Treating Patients With Mantle Cell Lymphoma	NCT00030875	Lymphoma	bortezomib	18 Years - 120 Years	Canadian Cancer Trials Group
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer	NCT00004061	Leukemia Lymphoma Oral Complicati...	filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera...	18 Years - 65 Years	National Cancer Institute (NCI)
Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma	NCT00020943	Lymphoma	filgrastim rituximab carmustine cyclophosphamid... cytarabine doxorubicin hyd... etoposide leucovorin calc... methotrexate prednisone vincristine sul... peripheral bloo...	18 Years - 69 Years	Alliance for Clinical Trials in Oncology
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma	NCT00006747	Graft Versus Ho... Lymphoma	carmustine melphalan etoposide cytarabine tacrolimus methotrexate sargramostim transplant	- 59 Years	Alliance for Clinical Trials in Oncology
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer	NCT00004061	Leukemia Lymphoma Oral Complicati...	filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera...	18 Years - 65 Years	National Cancer Institute (NCI)
Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma	NCT00053027	Lymphoma	rituximab cladribine	18 Years -	Alliance for Clinical Trials in Oncology
Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma	NCT00053092	Lymphoma	rituximab cyclophosphamid... fludarabine pho...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma	NCT00003311	Lymphoma	filgrastim cyclophosphamid... cytarabine dexamethasone doxorubicin hyd... methotrexate vincristine sul...	16 Years -	M.D. Anderson Cancer Center
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma	NCT00003338	Lymphoma	immunoscintigra... technetium Tc 9...	16 Years - 120 Years	Gilead Sciences
Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma	NCT00101101	Lymphoma	Cyclophosphamid... Doxorubicin Vincristine Prednisone Dexamethasone Autologous Tumo... IL-2	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma	NCT00017381	Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Stage I Adult D... Stage I Adult D... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenström Mac...	rituximab cyclophosphamid... filgrastim yttrium Y 90 ib... peripheral bloo...	18 Years - 70 Years	National Cancer Institute (NCI)
S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma	NCT01412879	Lymphoma	rituximab bendamustine hy... cyclophosphamid... cytarabine dexamethasone doxorubicin hyd... leucovorin calc... methotrexate vincristine sul...	18 Years - 65 Years	SWOG Cancer Research Network
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma	NCT00004197	Lymphoma	keyhole limpet ... sargramostim tumor cell-base... cyclophosphamid... doxorubicin hyd... mitoxantrone hy... prednisone vincristine sul...	18 Years - 120 Years	University of Nebraska
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan	NCT00577278	Graft Versus Ho... Leukemia Lymphoma	rituximab fludarabine pho... melphalan sirolimus tacrolimus allogeneic hema... indium In 111 i... yttrium Y 90 ib... laboratory biom...	18 Years - 69 Years	City of Hope Medical Center
R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma	NCT00450801	Lymphoma	Rituximab Cyclophosphamid... Cytarabine Doxorubicin Etoposide Ifosfamide Leucovorin Methotrexate Thalidomide Vincristine Mesna Filgrastim (G-C... Granisetron Decadron	18 Years -	University of Miami
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas	NCT02213913	Adult Grade III... B-cell Chronic ... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Progressive Hai... Small Intestine... Splenic Margina... Stage 0 Chronic... Stage I Adult D... Stage I Adult D... Stage I Adult D... Stage I Adult H... Stage I Adult I... Stage I Chronic... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage II Adult ... Stage II Chroni... Stage II Small ... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Chron... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Chroni... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Testicular Lymp... Untreated Hairy... Waldenström Mac...	lenalidomide etoposide prednisone vincristine sul... doxorubicin hyd... cyclophosphamid... rituximab quality-of-life... laboratory biom...	18 Years -	University of Chicago
Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma	NCT00110006	Lymphoma	rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... positron emissi... fludeoxyglucose...	18 Years -	Case Comprehensive Cancer Center
Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma	NCT00726700	Lymphoma	pegfilgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul...	61 Years - 80 Years	Universität des Saarlandes
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma	NCT01415752	Lymphoma Neurotoxicity Therapy-related...	rituximab bendamustine hy... bortezomib lenalidomide	60 Years - 120 Years	Eastern Cooperative Oncology Group
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma	NCT02037256	Adult Grade III... B-cell Chronic ... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Progressive Hai... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Hair... Refractory Mult... Small Intestine... Splenic Margina... Stage I Adult B... Stage I Adult D... Stage I Adult D... Stage I Adult D... Stage I Adult I... Stage I Adult L... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Multipl... Stage I Small L... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Untreated Hairy... Waldenström Mac...	bortezomib filgrastim autologous hema...	18 Years - 70 Years	Barbara Ann Karmanos Cancer Institute
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome	NCT00002989	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	busulfan cyclophosphamid... idarubicin melphalan radiation thera...	16 Years - 60 Years	National Cancer Institute (NCI)
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer	NCT00004132	Drug/Agent Toxi... Leukemia Lymphoma Multiple Myelom... Oral Complicati... Radiation Toxic...	filgrastim palifermin cyclophosphamid... etoposide ifosfamide quality-of-life... radiation thera...	12 Years - 65 Years	National Cancer Institute (NCI)
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma	NCT00026429	Leukemia Lymphoma	denileukin dift...	18 Years -	National Cancer Institute (NCI)
Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma	NCT00003337	Lymphoma	immunoscintigra... technetium Tc 9...	16 Years - 120 Years	Gilead Sciences
S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma	NCT00005089	Lymphoma	rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... radiation thera...	18 Years -	SWOG Cancer Research Network
Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma	NCT00433537	Contiguous Stag... Noncontiguous S... Stage I Mantle ... Stage III Mantl... Stage IV Mantle...	bortezomib rituximab cyclophosphamid... doxorubicin hyd... vincristine dexamethasone filgrastim pegfilgrastim Autologous stem...	18 Years -	National Cancer Institute (NCI)
Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma	NCT00004260	Lymphoma	recombinant int... rituximab	18 Years -	Mayo Clinic
Bortezomib in Treating Patients With Mantle Cell Lymphoma	NCT00030875	Lymphoma	bortezomib	18 Years - 120 Years	Canadian Cancer Trials Group
S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma	NCT00070018	Lymphoma	rituximab Cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... radiation thera... Yttrium-90 ibri... Indium-111 ibri...	18 Years -	SWOG Cancer Research Network
Oral Combination Chemotherapy in Treating Elderly Patients With Intermediate or High-Grade Non-Hodgkin's Lymphomas	NCT00003113	Lymphoma	filgrastim cyclophosphamid... etoposide lomustine procarbazine hy... radiation thera...	60 Years -	Case Comprehensive Cancer Center
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy	NCT00891137	Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic...	human myeloid p...	12 Years - 65 Years	Cellerant Therapeutics
Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma	NCT00003502	Contiguous Stag... Noncontiguous S... Stage III Mantl... Stage IV Mantle... Recurrent Mantl...	antineoplaston ... antineoplaston ... alternative pro... biological ther... biologically ba... cancer preventi... complementary a... differentiation...	18 Years -	National Cancer Institute (NCI)
Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma	NCT00720876	Lymphoma	rituximab vorinostat	18 Years -	City of Hope Medical Center
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma	NCT00003338	Lymphoma	immunoscintigra... technetium Tc 9...	16 Years - 120 Years	Gilead Sciences
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma	NCT00003338	Lymphoma	immunoscintigra... technetium Tc 9...	16 Years - 120 Years	Gilead Sciences
Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma	NCT00101101	Lymphoma	Cyclophosphamid... Doxorubicin Vincristine Prednisone Dexamethasone Autologous Tumo... IL-2	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma	NCT00028717	Lymphoma	filgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul...	65 Years -	National Cancer Institute (NCI)
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma	NCT00278408	Lymphoma	filgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... radiation thera...	18 Years - 60 Years	German High-Grade Non-Hodgkin's Lymphoma Study Group
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer	NCT00816413	Chronic Myelopr... Leukemia Lymphoma Myelodysplastic... Nonmalignant Ne...	cyclosporine mycophenolate m... pentostatin cytogenetic ana... fluorescence in... protein analysi... flow cytometry immunoenzyme te... laboratory biom... reduced-intensi... nonmyeloablativ... peripheral bloo... total-body irra...	19 Years - 75 Years	University of Nebraska
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma	NCT00278408	Lymphoma	filgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... radiation thera...	18 Years - 60 Years	German High-Grade Non-Hodgkin's Lymphoma Study Group
Gemcitabine in Treating Patients With Newly Diagnosed, Relapsed, or Chemotherapy-Resistant Mantle Cell Lymphoma	NCT00234026	Lymphoma	gemcitabine hyd...	18 Years -	Swiss Group for Clinical Cancer Research
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy	NCT00003341	Anemia Leukemia Lymphoma Multiple Myelom...	epoetin alfa quality-of-life...	18 Years -	Memorial Sloan Kettering Cancer Center
Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers	NCT00003572	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	peripheral bloo... mycophenolate m... tacrolimus allogeneic bone... radiation thera...	18 Years - 70 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma	NCT00058227	B-cell Chronic ... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Progressive Hai... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Chro... Refractory Hair... Splenic Margina... Stage I Chronic... Stage I Grade 1... Stage I Grade 2... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage II Chroni... Stage III Chron... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Chroni... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Untreated Hairy... Waldenström Mac...	alvocidib fludarabine pho... rituximab pharmacological...	18 Years -	National Cancer Institute (NCI)
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma	NCT00288067	Adult Nodular L... B-cell Chronic ... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Stage II Margin... Stage II Small ... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Chro... Splenic Margina... Stage I Adult B... Stage I Adult D... Stage I Adult H... Stage I Adult L... Stage I Chronic... Stage I Grade 1... Stage I Grade 2... Stage I Small L... Stage II Adult ... Stage II Chroni... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Chron... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Chroni... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenström Mac...	fenretinide rituximab	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: